ClinicalTrials.gg
RecruitingNCT07450859Updated Sep 18, 2026

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 2 interventional study of nuzefatide pevedotin (BT5528) in Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by BicycleTx Limited. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by BicycleTx Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
758th of 1,574
39 · median 37
Started
2026
with 83 others
Phase 2
488 of 1,851
45 open now
Primary completion
2029-03
later than 392 of 473 live
Registered
1,788th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 758th largest by planned enrollment of the 1,574 interventional ones that give a count, is one of 84 that started in 2026, is one of 488 in phase 2, reaches primary completion later than 392 of the 473 other live ones, and was the 1,788th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

295 more — sign in →

All 300 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or two prior lines of treatment if treated with KRAS inhibitor.

The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2.

The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.

Read the detailed description

This is a Phase 2, open-label, multicenter, single-arm study to evaluate the efficacy, safety, and pharmacokinetics (PK) of nuzefatide in adult participants with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on or after one prior line of systemic therapy in the metastatic setting or on or after second line therapy with a KRAS inhibitor in the metastatic setting. Nuzefatide is a novel Bicycle® drug conjugate (BDC®) that targets EphA2, a protein often found on cancer cells, and delivers a potent anti-cancer agent (MMAE).

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

  • Pancreatic Cancer
  • BT5528
  • EphA2
  • Bicycle Drug Conjugate
  • MMAE
  • Metastatic
  • Pancreatic Ductal Adenocarcinoma
  • PDAC
  • Nuzefatide Pevedotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age at the time of signature of the form (or at least 19 years where locally defined as minimum age of consent).
  • as defined by v1.1.
  • (ECOG) Performance Status of 0 or 1.
  • of at least 12 weeks.
  • confirmed pancreatic ductal adenocarcinoma (PDAC).
  • Participants must have failed whose disease has progressed on or after only 1 or on or after second line therapy with a KRAS inhibitor, with evidence of radiographic progression. or adjuvant systemic therapy may count as the first line if the participant progressed less than 6 months from the end of systemic therapy. Prior treatment with KRAS inhibitors in the first-line setting is permitted if there was no intervening treatment prior to enrollment.
  • Participants must have sufficient tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers.
  • Adequate organ function (hematologic, renal, and hepatic).
  • Negative pregnancy test for participants of (POCBP)
  • Must be willing and able to comply with the protocol and study procedures and agree to participate in the study by providing written informed consent.

Exclusion criteria

Exclusion Criteria

  • Chemotherapy or radiotherapy within 14 days prior to the first dose of study treatment
  • Experimental treatments within 28 days or 5 half-lives, whichever is longer, of first dose of nuzefatide study treatment
  • Prior treatment with taxane therapy (e.g., paclitaxel) for pancreatic cancer or prior treatment with any MMAE-containing agent
  • Known microsatellite instability-high (MSI-H) status and are eligible for therapy
  • Prior toxicities must have resolved to Grade 1 per National Cancer Institute (NCI) (CTCAE) v6.0
  • Untreated central nervous system (CNS)

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    nuzefatide pevedotin (BT5528) Monotherapy

    Drug: nuzefatide pevedotin (BT5528)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the Investigator

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Duration of Response (DoR) per RECIST v1.1

    The time from the first documentation of a tumor response (that is subsequently confirmed) to the first documentation of disease progression or death per RECIST v1.1

    Time frame: Up to approximately 3 years

  2. Overall Survival (OS)

    The length of time from the first day of study treatment (Day 1) to day of death

    Time frame: Up to approximately 3 years

  3. Disease Control Rate (DCR) per RECIST v1.1

    Percentage of participants who achieve a confirmed CR, PR, or stable disease (SD) per RECIST v1.1

    Time frame: Up to approximately 3 years

  4. Clinical Benefit Rate (CBR) per RECIST v1.1

    Defined as the proportion of participants with confirmed CR, PR, or SD ≥12 weeks per RECIST v1.1

    Time frame: Up to approximately 3 years

  5. Progression-Free Survival (PFS) per RECIST v1.1

    The time from the first day of study treatment to the first documentation of disease progression or death per RECIST v1.1

    Time frame: Up to approximately 3 years

  6. Time to Progression (TTP) per RECIST v1.1

    TTP defined as the time from first dose of nuzefatide until date of first documentation of disease progression per RECIST v1.1

    Time frame: Up to approximately 3 years

  7. Incidence of treatment-emergent adverse events (TEAEs)

    Proportion of participants experiencing an adverse event on treatment

    Time frame: Up to approximately 3 years

  8. Incidence of treatment-related adverse events (TRAEs)

    Proportion of participants experiencing an adverse event determined by the Investigator to be related to study treatment

    Time frame: Up to approximately 3 years

  9. Incidence of treatment emergent serious adverse events (TESAEs)

    Proportion of participants experiencing serious adverse events on treatment

    Time frame: Up to approximately 3 years

  10. Incidence of laboratory abnormalities

    Proportion of participants that experience abnormal laboratory values (blood chemistry (including liver function tests and creatinine clearance), hematology (including hemoglobin, neutrophil and platelet absolute counts)) on treatment

    Time frame: Up to approximately 3 years

  11. Incidence of ECG abnormalities

    Proportion of participants that experience abnormal ECG parameters on treatment

    Time frame: Up to approximately 3 years

  12. Incidence of abnormal vital signs

    Proportion of participants that have changes in vital signs such as blood pressure, heart rate, oxygen saturation, respiratory rate, and body temperature on treatment

    Time frame: Up to approximately 3 years

  13. Incidence of treatment modification due to adverse events

    Proportion of participants that require any treatment modification due to adverse events

    Time frame: Up to approximately 3 years

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 36 months is close to that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 5, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Mar 2029
CompletionEst.
May 2029
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450859
Lead sponsor
BicycleTx Limited
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Mar 5, 2026
Primary completion
Mar 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Sep 18, 2026

Study contacts

BicycleTx Limited
Contact
clinicalstudies@bicycletx.com
6179458155

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nuzefatide pevedotin

Start the discussion